Glucagon-like peptide-1 (GLP-1_ and GIP/GLP-1 agents are just the start: amylin- and glucagon-based mono-, dual-, and tri-therapies are on the horizon.
Robert Kushner, MD, MS
Advertisement
Articles by Robert Kushner, MD, MS
Advertisement
Latest Updated Articles
Advertisement
Advertisement
Trending on Pharmacy Times
1
New Lipid Drugs and What Pharmacists Need to Know
2
FDA Approves Tirzepatide to Cut CV Risk in Type 2 Diabetes
3
FDA Approves Ustekinumab Injection for Pediatric Ulcerative Colitis, Expanding IBD Options for Children
4
August 2026 in Oncology: FDA Approvals and Phase 3 Data Reshape Treatment Across Tumor Types
5